Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

Chinese biotech shares are surging this year on growing optimism over innovative cancer treatments being licensed to western ...

Hemostats market was valued at US$ 2,884.13 million in 2024 and is projected to hit the market valuation of US$ 4,839.68 million by 2033 at a CAGR of 5.92% during the forecast period 2025–2033.

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

The country’s biggest pharmaceuticals group pointed to “specific non-allied countries” and urged the White House to ...

Pfizer has boldly stepped into the burgeoning cannabis light market, giving the industry a serious growth spurt. The Cannabis ...

Sustainable change requires improved study design, market incentives, and patient involvement, write Kate Womersley and colleagues For too long, medical research has defaulted to male physiology, ...